News

Alzheimer drug improves memory
Enlarge image

Clinical trialsFinlandPoland

Alzheimer drug improves memory

14.03.2013 - Finnish Orion Pharma has presented Phase II results suggesting its first-in-class Alzheimer drug ORM-12741 improves memory.

A Phase IIa study on 100 patients with moderate Alzheimer's disease, which dosed the active arm with 60 milligrams or 200 milligrams of ORM-12741 plus standard cholinesterase treatment and memantine,  suggested a slight improvement (+4%) in memory tests. In contrast patients receiving placebo twice daily instead of ORM-12741 over three months worsened by 33%. 

Orion's candidate drug is the first to target the alpha-2C adrenergic receptor, which is expressed mainly in the CNS (striatum and hippocampus) and has a role as physiological fine tuner of synaptic neurotransmission.

"Currently, there are still only a handful of Alzheimer's drugs on the market and they have only moderate effects on the symptoms of the disease," said study author Dr. Juha Rouru of Orion Pharma. "Anytime you have a drug that targets a new pathway in the brain and shows effectiveness in clinical trials, it is exciting." 

Orion has already finished pre-clinical development of another alpha-2c adrenergic receptor in Alzheimer, which was licenced from Polish Selvita, and is in talks with potential partners who want to advance ORM-12741.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/alzheimer-drug-improves-memory.html

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FORMYCON13.90 EUR12.10%
  • MAGFORCE5.10 EUR7.82%
  • SANTHERA103.00 CHF5.64%

FLOP

  • CYTOS0.32 CHF-17.95%
  • CO.DON2.15 EUR-4.44%
  • MEDIGENE3.80 EUR-4.28%

TOP

  • ADDEX3.44 CHF47.6%
  • CYTOS0.32 CHF45.5%
  • FORMYCON13.90 EUR39.1%

FLOP

  • ACTELION100.70 CHF-15.1%
  • MOLOGEN5.72 EUR-13.7%
  • BIOFRONTERA2.02 EUR-12.2%

TOP

  • SANTHERA103.00 CHF2494.5%
  • BB BIOTECH248.45 EUR96.5%
  • FORMYCON13.90 EUR80.5%

FLOP

  • CYTOS0.32 CHF-90.3%
  • 4SC0.82 EUR-50.9%
  • MOLOGEN5.72 EUR-50.8%

No liability assumed, Date: 27.01.2015